Antiglaucoma Medication and Clinical Depression
| Autor: | Virginia Tuckwell, Isaac Schweitzer, Kay P. Maguire |
|---|---|
| Rok vydání: | 2001 |
| Předmět: |
Male
medicine.medical_specialty genetic structures Adrenergic beta-Antagonists Treatment withdrawal Glaucoma Betaxolol 03 medical and health sciences β1 adrenergic receptor 0302 clinical medicine Recurrence Humans Medicine 030212 general & internal medicine Intensive care medicine Depression (differential diagnoses) Aged Depressive Disorder Major Potential risk business.industry General Medicine medicine.disease 030227 psychiatry Psychiatry and Mental health Anesthesia Medical profession Sympatholytics Ophthalmic Solutions business medicine.drug |
| Zdroj: | Australian & New Zealand Journal of Psychiatry. 35:569-571 |
| ISSN: | 1440-1614 0004-8674 |
| DOI: | 10.1080/0004867010060503 |
| Popis: | Objective: The aim of this paper is to alert the medical community to the potential risk of clinical depression following the use of antiglaucoma medication. Method: The available literature concerning systemic side-effects of topical antiglaucoma medication and the association of these agents with clinical depression were reviewed. In addition, two cases are reported of the occurrence of clinical depression following use of topical betaxolol which only resolved completely after switching glaucoma medication. Results/Conclusions: The case reports presented here add to the increasing body of literature linking topical ophthalmic β-adrenoceptor antagonists with depression. While these cases are uncommon, this phenomenon continues to be poorly recognized by the medical profession, psychiatrists, ophthalmologists and general practitioners alike. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text